Syngene International Limited

NSEI:SYNGENE Stock Report

Market Cap: ₹339.8b

Syngene International Valuation

Is SYNGENE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SYNGENE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SYNGENE (₹846.9) is trading above our estimate of fair value (₹132.54)

Significantly Below Fair Value: SYNGENE is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SYNGENE?

Key metric: As SYNGENE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SYNGENE. This is calculated by dividing SYNGENE's market cap by their current earnings.
What is SYNGENE's PE Ratio?
PE Ratio70.5x
Earnings₹4.82b
Market Cap₹339.84b

Price to Earnings Ratio vs Peers

How does SYNGENE's PE Ratio compare to its peers?

The above table shows the PE ratio for SYNGENE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average52.2x
INDGN Indegene
41.1x18.4%₹153.3b
AKUMS Akums Drugs and Pharmaceuticals
34.5xn/a₹96.0b
DIVISLAB Divi's Laboratories
86.4x23.7%₹1.6t
INNOVACAP Innova Captab
46.8x29.7%₹55.4b
SYNGENE Syngene International
70.5x19.3%₹339.8b

Price-To-Earnings vs Peers: SYNGENE is expensive based on its Price-To-Earnings Ratio (70.5x) compared to the peer average (52.2x).

Price to Earnings Ratio vs Industry

How does SYNGENE's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
SYNGENE 70.5xIndustry Avg. 30.7xNo. of Companies7PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SYNGENE is expensive based on its Price-To-Earnings Ratio (70.5x) compared to the Asian Life Sciences industry average (30.7x).

Price to Earnings Ratio vs Fair Ratio

What is SYNGENE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYNGENE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio70.5x
Fair PE Ratio42.6x

Price-To-Earnings vs Fair Ratio: SYNGENE is expensive based on its Price-To-Earnings Ratio (70.5x) compared to the estimated Fair Price-To-Earnings Ratio (42.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SYNGENE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹846.90
₹862.50
+1.8%
14.9%₹1,030.00₹700.00n/a8
Nov ’25₹861.35
₹862.50
+0.1%
14.9%₹1,030.00₹700.00n/a8
Oct ’25₹909.25
₹760.63
-16.3%
13.0%₹925.00₹640.00n/a8
Sep ’25₹868.75
₹760.63
-12.4%
13.0%₹925.00₹640.00n/a8
Aug ’25₹828.50
₹766.22
-7.5%
12.4%₹925.00₹640.00n/a9
Jul ’25₹715.75
₹735.67
+2.8%
10.7%₹825.00₹620.00n/a9
Jun ’25₹672.10
₹735.67
+9.5%
10.7%₹825.00₹620.00n/a9
May ’25₹689.15
₹725.13
+5.2%
10.6%₹825.00₹620.00n/a8
Apr ’25₹708.40
₹745.14
+5.2%
7.3%₹811.00₹680.00n/a7
Mar ’25₹705.55
₹748.71
+6.1%
6.8%₹811.00₹680.00n/a7
Feb ’25₹746.60
₹750.14
+0.5%
7.0%₹811.00₹680.00n/a7
Jan ’25₹709.75
₹788.71
+11.1%
5.8%₹875.00₹731.00n/a7
Dec ’24₹746.70
₹782.63
+4.8%
5.8%₹875.00₹731.00n/a8
Nov ’24₹680.05
₹782.63
+15.1%
5.8%₹875.00₹731.00₹861.358
Oct ’24₹804.15
₹825.13
+2.6%
9.0%₹960.00₹740.00₹909.258
Sep ’24₹778.55
₹825.13
+6.0%
9.0%₹960.00₹740.00₹868.758
Aug ’24₹806.15
₹825.13
+2.4%
9.0%₹960.00₹740.00₹828.508
Jul ’24₹765.05
₹741.57
-3.1%
4.2%₹780.00₹695.00₹715.757
Jun ’24₹726.55
₹743.88
+2.4%
4.0%₹780.00₹695.00₹672.108
May ’24₹677.00
₹734.00
+8.4%
4.1%₹780.00₹695.00₹689.158
Apr ’24₹594.50
₹705.88
+18.7%
8.5%₹780.00₹610.00₹708.408
Mar ’24₹586.85
₹705.88
+20.3%
8.5%₹780.00₹610.00₹705.558
Feb ’24₹566.45
₹705.88
+24.6%
8.5%₹780.00₹610.00₹746.608
Jan ’24₹585.55
₹708.13
+20.9%
8.4%₹780.00₹590.00₹709.758
Dec ’23₹608.80
₹708.13
+16.3%
8.4%₹780.00₹590.00₹746.708
Nov ’23₹628.00
₹708.13
+12.8%
8.4%₹780.00₹590.00₹680.058

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Bal Pharma

₹2.1b

Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally.

BALPHARMA

₹134.50

7D

11.6%

1Y

27.4%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹911.45

7D

-3.5%

1Y

18.7%

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹298.65

7D

-1.3%

1Y

-16.9%